Agonists of the GLP-1 receptor have been proven useful mainly in situations where there is a limited ability to produce GLP-1, as observed in some insulin-resistance situations and obesity [42]. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.